source
- FDA cuts required analytical tests for emergency-use diagnostic devices in new guidanceOn 9 November 2026 the U.S. Food and Drug Administration released final guidance aimed at simplifying validation of in-vitro diagnostic devices used in public-health emergencies. The document outli…
- Kyorin signs $140M deal for Japan rights to Edesa's ARDS antibodyKyorin Pharmaceutical will pay $12 million up front and up to $134 million in milestones, plus royalties, for exclusive Japan rights to Edesa Biotech’s anti‑TLR4 antibody, paridiprubart, intended f…